BRPI0415754A - processo para preparar aripiprazol de tamanho de partìcula médio desejado - Google Patents

processo para preparar aripiprazol de tamanho de partìcula médio desejado

Info

Publication number
BRPI0415754A
BRPI0415754A BRPI0415754-0A BRPI0415754A BRPI0415754A BR PI0415754 A BRPI0415754 A BR PI0415754A BR PI0415754 A BRPI0415754 A BR PI0415754A BR PI0415754 A BRPI0415754 A BR PI0415754A
Authority
BR
Brazil
Prior art keywords
aripiprazole
particle size
average particle
preparing
desired average
Prior art date
Application number
BRPI0415754-0A
Other languages
English (en)
Inventor
Margaret M Gleeson
Soojin Kim
Donald Kientzler
San Kiang
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34549310&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0415754(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of BRPI0415754A publication Critical patent/BRPI0415754A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/02—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of powders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0004—Crystallisation cooling by heat exchange
    • B01D9/0009—Crystallisation cooling by heat exchange by direct heat exchange with added cooling fluid
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/005—Selection of auxiliary, e.g. for control of crystallisation nuclei, of crystal growth, of adherence to walls; Arrangements for introduction thereof
    • B01D9/0054—Use of anti-solvent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0063—Control or regulation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D9/00—Crystallisation
    • B01D9/0081—Use of vibrations, e.g. ultrasound
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2/00—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic
    • B01J2/02—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops
    • B01J2/06—Processes or devices for granulating materials, e.g. fertilisers in general; Rendering particulate materials free flowing in general, e.g. making them hydrophobic by dividing the liquid material into drops, e.g. by spraying, and solidifying the drops in a liquid medium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Thermal Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"PROCESSO PARA PREPARAR ARIPIPRAZOL DE TAMANHO DE PARTìCULA MéDIO DESEJADO". A presente invenção refere-se a um processo é fornecido para preparar aripiprazol estéril tendo um tamanho de partícula médio menor do que 100 mícrons porém preferivelmente maior do que 25 mícrons empregando um procedimento de cristalização a jato por colisão. O aripiprazol de massa resultante de tamanho de partícula desejado pode ser empregado para formar uma formulação de aripiprazol secada por congelamento estéril, que na constituição com água e injeção intramuscular libera aripiprazol durante um período de pelo menos cerca de uma semana e até cerca de oito semanas.
BRPI0415754-0A 2003-10-23 2004-10-20 processo para preparar aripiprazol de tamanho de partìcula médio desejado BRPI0415754A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51388603P 2003-10-23 2003-10-23
PCT/US2004/034634 WO2005041970A1 (en) 2003-10-23 2004-10-20 Process for making sterile aripiprazole of desired mean particle size

Publications (1)

Publication Number Publication Date
BRPI0415754A true BRPI0415754A (pt) 2006-12-19

Family

ID=34549310

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415754-0A BRPI0415754A (pt) 2003-10-23 2004-10-20 processo para preparar aripiprazol de tamanho de partìcula médio desejado

Country Status (16)

Country Link
US (3) US20050152981A1 (pt)
EP (1) EP1675593B1 (pt)
JP (1) JP4875984B2 (pt)
KR (1) KR101121345B1 (pt)
CN (1) CN1871007A (pt)
AR (1) AR046142A1 (pt)
AU (1) AU2004284904B2 (pt)
BR (1) BRPI0415754A (pt)
CA (1) CA2543248C (pt)
CO (1) CO5670354A2 (pt)
ES (1) ES2632499T3 (pt)
IL (1) IL175008A (pt)
MX (1) MXPA06004333A (pt)
PE (1) PE20050810A1 (pt)
TW (1) TWI371274B (pt)
WO (1) WO2005041970A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1613598E (pt) * 2003-12-16 2012-01-13 Teva Pharma Métodos para preparar formas cristalinas de aripiprazol
US7714129B2 (en) * 2003-12-16 2010-05-11 Teva Pharmaceutical Industries Ltd. Methods of preparing anhydrous aripiprazole form II
WO2005077904A1 (en) * 2004-02-05 2005-08-25 Teva Pharmaceutical Industries, Ltd. Process for preparing aripiprazole
US7507823B2 (en) * 2004-05-06 2009-03-24 Bristol-Myers Squibb Company Process of making aripiprazole particles
WO2006053781A1 (en) * 2004-11-18 2006-05-26 Synthon B.V. Process of making crystalline aripiprazole
WO2007035348A2 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
WO2007075871A2 (en) * 2005-12-22 2007-07-05 Teva Pharmaceutical Industries Ltd. Processes for reducing particle size of aripiprazole
US20080193518A1 (en) * 2006-04-28 2008-08-14 Schering Corporation Process for the precipitation and isolation of 6,6-Dimethyl-3-Aza Bicyclo [3.1.0] Hexane-Amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8420122B2 (en) 2006-04-28 2013-04-16 Merck Sharp & Dohme Corp. Process for the precipitation and isolation of 6,6-dimethyl-3-aza-bicyclo [3.1.0] hexane-amide compounds by controlled precipitation and pharmaceutical formulations containing same
US8039621B2 (en) * 2006-10-24 2011-10-18 Cambrex Charles City, Inc. Process for preparing anhydrous Aripirazole type I
CN101172966B (zh) * 2007-04-06 2012-08-29 重庆医药工业研究院有限责任公司 一种阿立哌唑微晶的制备方法
LT2170279T (lt) 2007-07-31 2018-03-12 Otsuka Pharmaceutical Co., Ltd. Aripiprazolo suspensijos ir liofilizuotos kompozicijos gamybos būdai
GB0909154D0 (en) * 2008-09-25 2009-07-08 Nanomaterials Tech Pte Ltd A process for making particles for delivery of drug nanoparticles
DE102009008478A1 (de) * 2009-02-11 2010-08-19 PHAST Gesellschaft für pharmazeutische Qualitätsstandards mbH Vorrichtung und Verfahren zur Herstellung pharmazeutisch hochfeiner Partikel sowie zur Beschichtung solcher Partikel in Mikroreaktoren
CN101507908B (zh) * 2009-04-09 2010-12-01 北京化工大学 微通道套管式装置及其应用
PL2550092T3 (pl) * 2010-03-22 2019-01-31 Instillo Gmbh Sposób wytwarzania mikro- lub nanocząstek
CN101816913B (zh) * 2010-05-20 2015-10-21 吴传斌 一种微球制造方法及制造设备
JP5575269B2 (ja) 2010-08-24 2014-08-20 大塚製薬株式会社 カルボスチリル誘導体並びにシリコーンオイル及び／又はシリコーンオイル誘導体を含有する懸濁液及びケーキ組成物
US9469630B2 (en) 2010-10-18 2016-10-18 Sumitomo Dainippon Pharma Co., Ltd. Sustained-release formulation for injection
CN105125509B (zh) * 2011-01-24 2019-01-11 大塚制药株式会社 以阿立哌唑作为有效成分的块状组合物
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
CN102850268B (zh) 2011-06-27 2015-07-15 上海中西制药有限公司 阿立哌唑ⅰ型微晶、阿立哌唑固体制剂及制备方法
US9241876B2 (en) 2011-06-27 2016-01-26 Shanghai Zhongxi Pharmaceutical Corporation Aripiprazole medicament formulation and preparation method therefor
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
US9732068B1 (en) * 2013-03-15 2017-08-15 GenSyn Technologies, Inc. System for crystalizing chemical compounds and methodologies for utilizing the same
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
SMT202100212T1 (it) * 2014-08-25 2021-07-12 Alkermes Pharma Ireland Ltd Processo di cristallizzazione di derivati di aripiprazolo in formulazioni a rilascio prolungato per il trattamento di schizofrenia
JP6758325B2 (ja) * 2015-06-04 2020-09-23 クリティテック・インコーポレイテッド タキサン粒子およびその使用
US20190160002A1 (en) 2016-07-28 2019-05-30 Mylan Laboratories Limited Process for preparing sterile aripiprazole formulation
CN111346397B (zh) * 2020-03-11 2022-03-29 天津大学 适用于溶析结晶或反应结晶的加料设备

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
JP3282731B2 (ja) * 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
JP3862957B2 (ja) * 1999-01-29 2006-12-27 ブリストル−マイヤーズ スクイブ カンパニー 音波衝突ジェット結晶化装置及び方法
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
CZ20011726A3 (cs) * 2000-05-26 2002-02-13 Pfizer Products Inc. Způsob reakční krystalizace, který umoľňuje řídit velikost částic
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
WO2003092852A1 (en) * 2002-04-29 2003-11-13 Bristol-Myers Squibb Company Crystallization system utilizing atomization
CA2485418A1 (en) * 2002-05-10 2003-11-20 Bristol-Myers Squibb Company Crystallization system using homogenization
WO2004083183A1 (en) * 2003-03-21 2004-09-30 Hetero Drugs Limited Novel crystalline forms of aripiprazole
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole

Also Published As

Publication number Publication date
TWI371274B (en) 2012-09-01
KR101121345B1 (ko) 2012-03-09
CA2543248C (en) 2013-04-02
CO5670354A2 (es) 2006-08-31
JP4875984B2 (ja) 2012-02-15
US20050152981A1 (en) 2005-07-14
CN1871007A (zh) 2006-11-29
IL175008A (en) 2014-11-30
IL175008A0 (en) 2006-08-20
AU2004284904B2 (en) 2010-05-20
EP1675593A1 (en) 2006-07-05
CA2543248A1 (en) 2005-05-12
TW200518783A (en) 2005-06-16
US20130161848A1 (en) 2013-06-27
AU2004284904A1 (en) 2005-05-12
WO2005041970A1 (en) 2005-05-12
KR20070090070A (ko) 2007-09-05
MXPA06004333A (es) 2006-06-05
EP1675593A4 (en) 2007-04-25
AR046142A1 (es) 2005-11-23
PE20050810A1 (es) 2005-09-25
ES2632499T3 (es) 2017-09-13
US9066848B2 (en) 2015-06-30
JP2007509153A (ja) 2007-04-12
US20110166352A1 (en) 2011-07-07
EP1675593B1 (en) 2017-05-31

Similar Documents

Publication Publication Date Title
TW200518783A (en) Process for making sterile aripiprazole of desired mean particle size
BR9908625A (pt) Processo para produção de uma formulação lìquida de tetrafenilfosfÈniofenolato
BRPI0415531A (pt) método e formulação de aripiprazol injetável estável estéril de liberação controlada
BR0001919A (pt) Composição de creme de limpeza de pele de modo que forme espuma, e, sistema de limpeza espumante de pele.
BR0011347A (pt) Preparações e formas de administração compreendendo um composto ativo de ácido instável
BRPI0000126B8 (pt) composição de vacina, composição adjuvante e método de produção de uma composição de vacina
BR0013826A (pt) Formas orais de apresentação
BRPI0901506A2 (pt) material de apoio para um instrumento cirúrgico
BR0014014A (pt) Tecido de velo para a fabricação de revestimento de proteção de espaço limpo
BR0115482A (pt) Composição de sacralose melhorada e processo para sua preparação
BR0009486B1 (pt) composto que compreende uma amida, composição farmacêutica que compreende esse composto, seu uso e processo para a preparação do mesmo.
BRPI0400721A (pt) Composições que contêm sucralose
BRPI0512864A (pt) composições e métodos para o tratamento de condições e desordens oculares
CL2009000555A1 (es) Compuestos derivados de tetramatos sustituidos espirociclicamente con 4'4'-dioxaespiro; procedimiento de preparacion; agente para combatir plagas y/o vegetaciones indeseadas que comprende dichos compuestos; su procedimiento de preparacion y uso; composiciones y su uso
BR0203785A (pt) ácido silìcico precipitante com elevada proporção bet/ctab
BR9813811A (pt) "composições farmacêuticas compreendendo micelas que compreendem glicocorticosteróide lipofìlico e apenas um único tensoativo"
BRPI0410391A (pt) derivados (2-hidróxi-2-(4-hidróxi-3-hidroximetilfenil)-etilamino)- propilfenila como agonistas beta2
BRPI0414479A (pt) métodos para produzir uma vitro-cerãmica e para produzir partìculas abrasivas
BRPI0418303A (pt) garra intramedular
BRPI9814894A (pt) processo para a preparação de ácidos 8-metóxi-quinolonocarboxílicos.
BR0008872A (pt) Processo para a produção de formas de dosagem sólidas, e, forma de dosagem sólida
BR0212807A (pt) Processo para a preparação de formas de dosagem de dissolução rápida
ATE373466T1 (de) Lipidträgerzusammensetzungen und verfahren zur verbesserten wirkstoffzurückhaltung
BR0008255A (pt) Composição e processo para formar emulsão estável sob cisalhamento
AR041255A1 (es) Indoles 2,7 sustituidos. metodo de obtencion y su uso como medicamento para trastornos del sistema nervioso.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/496; C07D 401/00; A61P 25/00

Ipc: A61K 31/496 (2011.01), C07D 401/00 (2011.01), A61P

B25A Requested transfer of rights approved

Owner name: OTSUKA PHARMACEUTICAL CO., LTD. (JP)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2484 DE 14-08-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.